Dystrophic serotonin axons in postmortem brains from young autism patients

Anatomical Record

Volumn 294, Issue 10, 2011, Pages 1653-1662

  Azmitia, Efrain C ^a   Singh, Jorawer S ^a   Hou, Xiao P ^a   Wegiel, Jerzy ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Autism; Brain; Human; Postmortem; Serotonin

Indexed keywords

SEROTONIN;

AMYGDALOID NUCLEUS; ARTICLE; AUTISM; AUTOPSY; BRAIN DEVELOPMENT; BRAIN TISSUE; CELL STRUCTURE; CORTICAL FIBER; DEGENERATIVE DISEASE; DYSTROPHY; HUMAN; NERVE FIBER; NEUROPATHOLOGY; NONHUMAN; PARAHIPPOCAMPUS; PRIORITY JOURNAL; PYRIFORM CORTEX; SEROTONINERGIC NERVE CELL; SUPERIOR TEMPORAL GYRUS;

ADOLESCENT; ADULT; AUTISTIC DISORDER; BRAIN; CHILD; CHILD, PRESCHOOL; HUMANS; NEUROAXONAL DYSTROPHIES; NEURODEGENERATIVE DISEASES; SEROTONIN; YOUNG ADULT;

ANIMALIA;

EID: 80053002788     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.21243     Document Type: Article

References (111)

1. Aan het Rot M, Mathew SJ, Charney DS. 2009. Neurobiological mechanisms in major depressive disorder. CMAJ 180: 305-313.
2. Akbari HM, Kramer HK, Whitaker-Azmitia PM, Spear LP, Azmitia EC. 1992. Prenatal cocaine exposure disrupts the development of the serotonergic system. Brain Res 572: 57-63.
3. Anderson GM, Freedman DX, Cohen DJ, Volkmar FR, Hoder EL, McPhedran P, Minderaa RB, Hansen CR, Young JG. 1987. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 28: 885-900.
4. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. 2007. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 62: 711-721.
5. Austin MC, Whitehead RE, Edgar CL, Janosky JE, Lewis DA. 2002. Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience 114: 807-815.
6. Azmitia EC. 1999. Serotonin neurons, neuroplasticity, and homeostasis of neural tissue. Neuropsychopharmacology 21: 33S-45S.
7. Azmitia EC, Gannon PJ. 1986. The primate serotonergic system: a review of human and animal studies and a report on Macaca fascicularis. Adv Neurol 43: 407-468.
8. Azmitia EC, Nixon R. 2008. Dystrophic serotonergic axons in neurodegenerative diseases. Brain Res 1217: 185-194.
9. Azmitia EC, Segal M. 1978. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 179: 641-667.
10. Bagdy G, Kecskemeti V, Riba P, Jakus R. 2007. Serotonin and epilepsy. J Neurochem 100: 857-873.
11. Baghdadli A, Pascal C, Grisi S, Aussilloux C. 2003. Risk factors for self-injurious behaviours among 222 young children with autistic disorders. J Intellect Disabil Res 47: 622-627.
12. Bailey A, Luthert P, Dean A, Harding B, Janota I, Montgomery M, Rutter M, Lantos P. 1998. A clinicopathological study of autism. Brain 121: 889-905.
13. Bauman ML, Kemper TL. 1994. Neuroanatomic observations of the brain in autism. In: Bauman ML, Kemper TL, editors. The neurobiology of autism. Johns Hopkins University Press.
14. Bauman ML, Kemper TL. 2005. Neuroanatomic observations of the brain in autism: a review and future directions. Int J Dev Neurosci 23: 183-187.
15. Becker LE, Armstrong DL, Chan F. 1986. Dendritic atrophy in children with Down's syndrome. Ann Neurol 20: 520-526.
16. Block ML, Hong JS. 2005. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76: 77-98.
17. Boylan CB, Blue ME, Hohmann CF. 2007. Modeling early cortical serotonergic deficits in autism. Behav Brain Res 176: 94-108.
18. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. 1997. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol 7: 109-121.
19. Carneiro AM, Cook EH, Murphy DL, Blakely RD. 2008. Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 118: 1544-1552.
20. Chandana SR, Behen ME, Juhasz C, Muzik O, Rothermel RD, Mangner TJ, Chakraborty PK, Chugani HT, Chugani DC. 2005. Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism. Int J Dev Neurosci 23: 171-182.
21. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM. 1993. Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 54: 691-699.
22. Cho IH, Yoo HJ, Park M, Lee YS, Kim SA. 2007. Family-based association study of 5-HTTLPR and the 5-HT2A receptor gene polymorphisms with autism spectrum disorder in Korean trios. Brain Res 1139: 34-41.
23. Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT. 1999. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 45: 287-295.
24. Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, da Silva EA, Chugani HT. 1997. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol 42: 666-669.
25. Courchesne E, Carper R, Akshoomoff N. 2003. Evidence of brain overgrowth in the first year of life in autism. JAMA 290: 337-344.
26. Courchesne E, Karns C, Davis H, Ziccardi R, Carper R, Tigue Z, Chisum HJ, Moses P, Pierce K, Lord C, Lincoln AJ, Pizzo S, Schreibman L, Haas RH, Akshoomoff NA, Courchesne RY. 2001. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology 57: 245-254.
27. Courchesne E, Redcay E, Morgan JT, Kennedy DP. 2005. Autism at the beginning: microstructural and growth abnormalities underlying the cognitive and behavioral phenotype of autism. Dev Psychopathol 17: 577-579.
28. Coutinho AM, Sousa I, Martins M, Correia C, Margadinho T, Bento C, Marques C, Ataíde A, Miguel TS, Moore JH, Oliveria G, Vicente AM. 2007. Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Hum Genet 121: 243-256.
29. Crane L, Goddard L, Pring L. 2009. Sensory processing in adults with autism spectrum disorders. Autism 13: 215-228.
30. Cross S, Kim SJ, Weiss LA, Delahanty RJ, Sutcliffe JS, Leventhal BL, Cook EH Jr, Veenstra-Vanderweele J. 2008. Molecular genetics of the platelet serotonin system in first-degree relatives of patients with autism. Neuropsychopharmacology 33: 353-360.
31. Davis E, Fennoy I, Laraque D, Kanem N, Brown G, Mitchell J. 1992. Autism and developmental abnormalities in children with perinatal cocaine exposure. J Natl Med Assoc 84: 315-319.
32. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. 2003. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60: 443-456.
33. Devlin B, Cook EH, Jr, Coon H, Dawson G, Grigorenko EL, McMohan W, Minshew N, Pauls D, Smith M, Spence MA, Rodier PM, Stodgell C, Schellenberg GD, CPEA Genetic Network. 2005. Autism and the serotonin transporter: the long and short of it. Mol Psychiatry 10: 1110-1116.
34. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Tredici KD, Wszolek ZK, Litvan I. 2009. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 8: 1150-1157.
35. Eriksen JL, Gillespie R, Druse MJ. 2002. Effects of ethanol and 5-HT1A agonists on astroglial S100B. Brain Res Dev Brain Res 139: 97-105.
36. Esaki T, Cook M, Shimoji K, Murphy DL, Sokoloff L, Holmes A. 2005. Developmental disruption of serotonin transporter function impairs cerebral responses to whisker stimulation in mice. Proc Natl Acad Sci USA 102: 5582-5587.
37. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. 2006. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 81: 47-63.
38. Goddard AW, Shekhar A, Whiteman AF, McDougle CJ. 2008. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov Today 13: 325-332.
39. Goldberg J, Anderson GM, Zwaigenbaum L, Hall GB, Nahmias C, Thompson A, Szatmari P. 2009. Cortical serotonin type-2 receptor density in parents of children with autism spectrum disorders. J Autism Dev Disord 39: 97-104.
40. Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, Houle S, Wilson A, Mundo E, Rusjan P, Meyer J, Kish SJ. 2007. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 14: 523-528.
41. Haapaniemi TH, Ahonen A, Tomiainen P, Sotaniemi KA, Myllylä VV. 2001. [123I]β-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 16: 124-130.
42. Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, Blessing WW, Geffen LB. 1990. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 4: 373-385.
43. Hanley HG, Stahl SM, Freedman DX. 1977. Hyperserotonemia and amine metabolites in autistic and retarded children. Arch Gen Psychiatry 34: 521-531.
44. Hansen MB. 2003. The enteric nervous system II: gastrointestinal functions. Pharmacol Toxicol 92: 249-257.
45. Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, Suzuki K, Minabe Y, Takei N, Iyo M, Mori N. 2006. Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 30: 1529-1531.
46. Hranilovic D, Bujas-Petkovic Z, Vragovic R, Vuk T, Hock K, Jernej B. 2007. Hyperserotonemia in adults with autistic disorder. J Autism Dev Disord 37: 1934-1940.
47. Hutchinson M, Raff U. 1999. Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra. J Neurol Neurosurg Psychiatry 67: 815-818.
48. Huttenlocher PR. 2000. The neuropathology of phenylketonuria: human and animal studies. Eur J Pediatr 159 Suppl 2: S102-S106.
49. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. 2009. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 1181: 53-69.
50. Janusonis S. 2008. Origin of the blood hyperserotonemia of autism. Theor Biol Med Model 5: 10.
51. Janusonis S, Anderson GM, Shifrovich I, Rakic P. 2006. Ontogeny of brain and blood serotonin levels in 5-HT receptor knockout mice: potential relevance to the neurobiology of autism. J Neurochem 99: 1019-1031.
52. Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. 2005. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29: 846-858.
53. Jones CR, Happé F, Baird G, Simonoff E, Marsden AJ, Tregay J, Phillips RJ, Goswami U, Thomson JM, Charman T. 2009. Auditory discrimination and auditory sensory behaviours in autism spectrum disorders. Neuropsychologia 47: 2850-2858.
54. Kanner L. 1943. Autistic disturbances of affective contact. Nerv Child 2 (1943): 2217-2250.
55. Kanold PO. 2004. Transient microcircuits formed by subplate neurons and their role in functional development of thalamocortical connections. Neuroreport 15: 2149-2153.
56. Kemper TL, Bauman ML. 1998. Neuropathology of infantile autism. J Neuropathol Exp Neurol 57: 645-652.
57. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L. STAART Psychopharmacology Network. 2009. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 66: 583-590.
58. Kolevzon A, Newcorn JH, Kryzak L, Chaplin W, Watner D, Hollander E, Smith CJ, Cook EH, Jr., Silverman JM. 2010. Relationship between whole blood serotonin and repetitive behaviors in autism. Psychiatry Res 175: 274-276.
59. Kosofsky BE, Molliver ME. 1987. The serotonergic innervation of cerebral cortex: different classes of axon terminals arise from dorsal and median raphe nuclei. Synapse 1: 153-168.
60. Kotzbauer PT, Trojanowsk JQ, Lee VM. 2001. Lewy body pathology in Alzheimer's disease. J Mol Neurosci 17: 225-232.
61. Kumra S, Ashtari M, Cervellione KL, Henderson I, Kester H, Roofeh D, Wu J, Clarke T, Thaden E, Kane JM, Rhinewine J, Lencz T, Diamond A, Ardekani BA, Szeszko PR. 2005. White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry 44: 934-941.
62. Lam KS, Aman MG, Arnold LE. 2006. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 27: 254-289.
63. Lees AJ, Hardy J, Revesz T. 2009. Parkinson's disease. Lancet 373: 2055-2066.
64. Leger L, Charnay Y, Hof PR, Bouras C, Cespuglio R. 2001. Anatomical distribution of serotonin-containing neurons and axons in the central nervous system of the cat. J Comp Neurol 4332: 157-182.
65. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpé S, Maes M. 1998. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32: 9-15.
66. López-Hurtado E, De Felipe J, Prieto JJ. 2002. A microscopical study on the neuroanatomical abnormalities of language related cortical areas in autistic patients. In: IMFAR, International Meeting for Autism Research, November 1-2, Orlando, FL.
67. Lowry CA, Hale MW, Evans AK, Heerkens J, Staub DR, Gasser PJ, Shekhar A. 2008. Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann NY Acad Sci 1148: 86-94.
68. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RCS, Paul IA. 2006. Neonatal Antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 31: 47-57.
69. Marin-Padilla M. 1976. Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. J Comp Neurol 167: 63-81.
70. McCaffery P, Deutsch CK. 2005. Macrocephaly and the control of brain growth in autistic disorders. Prog Neurobiol 77: 38-56.
71. McNamara IM, Borella AW, Bialowas LA, Whitaker-Azmitia PM. 2008. Further studies in the developmental hyperserotonemia model (DHS) of autism: social, behavioral and peptide changes. Brain Res 1189: 203-214.
72. Ming X, Brimacombe M, Chaaban J, Zimmerman-Bier B, Wagner GC. 2008. Autism spectrum disorders: concurrent clinical disorders. J Child Neurol 23: 6-13.
73. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA. 1990. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 600: 649-661.
74. Morrison JH, Magistretti PJ. 1983. Monoamines and peptides in cerebral cortex-contrasting principles of cortical organization. Trends Neurosci 6: 146-151.
75. Nanson JL. 1992. Autism in fetal alcohol syndrome: a report of six cases. Alcohol Clin Exp Res 16: 558-565.
76. Narayan S, Tang B, Head SR, Gilmartin TJ, Sutcliffe JG, Dean B, Thomas EA. 2008. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res 1239: 235-248.
77. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL, Phillips TM. 2001. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 49: 597-606.
78. Nurun BN, Tanaka T, Kamino K, Sadik G, Ansar AB, Kimura R, Tanii H, Okochi M, Morihara T, Tagami S, Kudo T, Takeda M. 2006. Toll-like receptor 3 mediated hyperphosphorylation of tau in human SH-SY5Y neuroblastoma cells. Psychiatry Clin Neurosci 60: S27-S33.
79. Ohama E, Ikuta F. 1976. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol 34: 311-319.
80. Oliver C, Holland AJ. 1986. Down's syndrome and Alzheimer's disease: a review. Psychol Med 16: 307-322.
81. Palmen SJMC, van Engeland PR, Hof PR, Schmitz C. 2004. Neuropathological findings in autism. Brain 127: 2572-2583.
82. Pattij T, Vanderschuren LJ. 2008. The neuropharmacology of impulsive behaviour. Trends Pharmacol Sci 29: 192-199.
83. Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J. 2005. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci 239: 11-19.
84. Perl DP. 2010. Neuropathology of Alzheimer's disease. Mt Sinai J Med 77: 32-42.
85. Pickett J, London E. 2005. The neuropathology of autism: a review. J Neuropathol Exp Neuro 64: 925-935.
86. Purpura DP. 1975. Dendritic differentiation in human cerebral cortex: normal and aberrant developmental patterns. In: Kreutzberg GW, editor. Physiology and pathology of dendrites. Adv. Neurol. 12: 91-116.
87. Raymond G, Bauman ML, Kemper TL. 1989. The hippocampus in autism: Golgi analysis. Acta Neuropathol 91: 117-119.
88. Reynolds S, Lane SJ. 2008. Diagnostic validity of sensory over-responsivity: a review of the literature and case reports. J Autism Dev Disord 3: 516-529.
89. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. 1983. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275: 321-328.
90. Schain RJ, Freedman DX. 1961. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 58: 315-320.
91. Schumann CM, Amaral DG. 2006. Stereological analysis of amygdala neuron number in autism. J Neurosci 2629: 7674-7679.
92. Schumann CM, Hamstra J, Goodlin-Jones BL, Lotspeich LJ, Kwon H, Buonocore MH, Lammers CR, Reiss AL, Amaral DG. 2004. The amygdala is enlarged in children but not adolescents with autism; the hippocampus is enlarged at all ages. J Neurosci 24: 6392-6401.
93. Sieve LJ. 2008. Neurobiology of aggression and violence. Am J Psychiatry 165: 429-442.
94. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. 2008. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47: 921-929.
95. Singh V, Mukherjee L, Chung MK. 2008. Cortical surface thickness as a classifier: boosting for autism classification. Med Image Comput Comput Assist Interv. 11: 999-1007.
96. Spivak B, Golubchik P, Mozes T, Vered Y, Nechmad A, Weizman A, Strous. 2004. Low platelet-poor plasma levels of serotonin in adult autistic patients. Neuropsychobiology 50: 157-160.
97. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B. 2008. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatry Res 42: 151-157.
98. Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, McCusker E, Frackowiak RS. 2002. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 125: 1815-1828.
99. Tuchman R, Rapin I. 1997. Regression in pervasive developmental disorders: seizures and epileptiform electroencephalogram correlates. Pediatrics 99: 560-566.
100. Ueda S, Kawata M. 1994. Regeneration of serotonergic immunoreactive fibers in the brain of 5, 6-dihydroxytryptamine treated rat. J Hirnforsch 351: 159-180.
101. Van Kooten IA, Palmen SJ, von Cappeln P, Steinbusch HW, Korr H, Heinsen H, Hof PR, van Engeland H, Schmitz C. 2008. Neurons in the fusiform gyrus are fewer and smaller in autism. Brain 131: 987-999.
102. Vargas DL, Nascimbene C, Krishnan C, Zimmerman A, Pardo CA. 2005. Increased neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57: 67-81.
103. Wassink TH, Hazlett HC, Epping EA, Arndt S, Dager SR, Schellenberg GD, Dawson G, Piven J. 2007. Cerebral cortical gray matter overgrowth and functional variation of the serotonin transporter gene in autism. Arch Gen Psychiatry 64: 709-717.
104. Wegiel J, Kuchna I, Nowicki K, Imaki H, Wegiel J, Marchi E, Ma SY, Chauhan A, Chauhan V, Bobrowicz TW, de Leon M, Louis LA, Cohen IL, London E, Brown WT, Wisniewski T. 2010. The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol. 119: 755-770.
105. Weiss LA, Kosova G, Delahanty RJ, Jiang L, Cook EH, Ober C, Sutcliffe JS. 2006. Variation in ITGB3 is associated with whole-blood serotonin level and autism susceptibility. Eur J Hum Genet 14: 923-931.
106. West L, Brunssen SH, Waldrop J. 2009. Review of the evidence for treatment of children with autism with selective serotonin reuptake inhibitors. J Spec Pediatr Nurs 14: 183-191.
107. Whitaker-Azmitia PM. 2001. Serotonin and brain development: role in human developmental diseases. Brain Res Bull 56: 479-485.
108. Whitaker-Azmitia PM. 2005. Behavioral and cellular consequences of increasing serotonergic activity during brain development: a role in autism? Int J Dev Neurosci 23: 75-83.
109. Whitehouse AJ, Bishop DV. 2008. Cerebral dominance for language function in adults with specific language impairment or autism. Brain 131: 3193-3200.
110. Wisniewski K. 1990. Down syndrome children often have brain with maturation delay, retardation of growth and cortical dysgenesis. Am J Med Genet 7: 274-281.
111. Zhou FC, Sari Y, Powrozek T, Goodlett CR, Li TK. 2003. Moderate alcohol exposure compromises neural tube midline development in prenatal brain. Brain Res Dev Brain Res 1441: 43-55.